About Us

Our Mission

Bring consistency, high-quality and standardization to make medical cannabis accessible for those who need it. 

Panaxia is modernizing the medical field with revolutionary pharmaceutical solutions that utilize the unique properties and benefits of medical cannabis. As a leader in this rapidly developing medical arena, Panaxia is spearheading the adoption of cannabis-based treatments through a variety of familiar delivery methods that can radically improve the lives of those with a wide range of medical conditions.

Our Story

Decades of experience to lead the way forward.

 Leveraging over four decades of experience in the pharmaceutical industry, Panaxia is part of a leading group of Israeli pharmaceutical companies. Thanks to our relentless emphasis on research and development, today our entire group of companies offers more than 600 medical products in over 30 international markets to treat a wide range of symptoms and conditions.

Our Quest

Research. Develop. Repeat.

 As pharmaceutical research on cannabis continues to evolve, we intend to stay at the forefront of the field. With over 20 percent of our workforce dedicated to research and development, we are committed to continuously increasing our knowledge and understanding of this plant’s wide range of therapeutic benefits. Our goal is to increase accessibility to pharmaceutical cannabis with cutting-edge products and a variety of new and familiar delivery methods.

Our Commitment

Quality and accuracy caregivers and patients can depend on.

 As with any other pharmaceutical product, standardization, consistency, and accuracy of dosage are essential. Until now, the absence of these fundamental attributes has limited cannabis’ therapeutic potential. Panaxia is committed to changing all that. By using the most advanced analytical and validation methods, we are developing dosage forms that deliver the same amount of active ingredients to patients time after time.

Our Team.
Led by Experience.

Executive Team

Dr Dadi Segal 67

Dr. Dadi Segal, PhD
CEO & Founder 
PhD: Computational Chemistry    

Assi Rotbart 15

Assi Rotbart
General Manager

Gil Benyamini 59

Gil Benyamini
CFO

Dr Eran Goldberg 61

Dr. Eran Goldberg, PhD
CTO
PhD: Plant Sciences

Board of Directors

Jonathan Kolber
Board, Chairman
Viola Growth,  General Partner

Orit Weissman
Board 
Goldman Sachs,  Partner & Head of Israel

Scientific Advisors

Prof. Aaron Ciechanover
Chemistry
Nobel Prize Laureate in Chemistry and Distinguished Research Israel Institute of Technology, Professor

Prof. David (Dedi) Meiri
Cancer Biology and Cannabinoid Research
Biology and Cannabinoid Research Laboratory of Cancer

Prof. Markus Veit, PhD
Pharmaceutical Chemistry

Herbal medicinal products and
plant phenolics. 
Founder, Alphatopics, GmbH

Dr. Noa Leibobvitch
Product Development

PhD: Physiology & Pharmacology.  Teva, Global Head of Branded Product Development

Scientific Team Leaders

Dr. Lior Zelikovich
Chief Scientific Officer
PhD: Organic Chemistry

Dr. Malgorzata Meunier
Pharmaceutical Sciences
PhD: Pharmaceutical Sciences

Dr. Shifra Jammer
Chemistry
PhD: Chemistry

Dr. Sheina Tarlovski
Medical Expert

MD: Doctor of Medicine